Uppsala university hospital and sana biotechnology announce authorization of the first-in-human clinical trial application for a primary islet cell treatment for patients with type 1 diabetes

Goal is to report up421 proof of concept data in 2023 and 2024 potential to remove immunosuppression from islet cell transplantation seattle, nov. 17, 2023 (globe newswire) -- sana biotechnology, inc. (nasdaq: sana), a company focused on changing the possible for patients through engineered cells, and uppsala university hospital in sweden today announced the swedish medical products agency has authorized uppsala university's clinical trial application (cta) to initiate an investigator-sponsored, first-in-human study of up421, an allogeneic, primary islet cell therapy engineered with sana's hypoimmune (hip) technology, in patients with type 1 diabetes. the goal of up421 treatment is to provide proof of concept for transplanting functional islet cells without immunosuppression.
SANA Ratings Summary
SANA Quant Ranking